

ExpreS²ion will participate in key industry and investor events

Hørsholm, Denmark, November 15, 2022 – ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") will participate and hold presentations at key industry and investor events in the coming month. These include PEGS Europe Protein & Antibody Engineering Summit (November 14-16), the presentation of Q3 2022 results (November 17), and the BioStock Life Science Summit 2022 (November 29-30).

By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS² technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company's [website](#).

PEGS Europe - Protein & Antibody Engineering Summit, November 14-16, Barcelona, Spain

Meet ExpreS²ion's VP of R&D and Technology, Dr. Max M. Søgaard at the largest protein & antibody engineering event in Europe. More information and registration can be found on the [PEGS Europe website](#).

Presentation of Q3 2022 results hosted by HC Andersen Capital, November 17 at 10:00 CET, Virtual

ExpreS²ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q3 2022 results and answer investors' questions. More information and registration can be found on the [H.C. Andersen Capital Events website](#).

BioStock Life Science Summit 2022, November 30 at 14:40 CET, Medicon Village, Lund, Sweden

CEO Bent U. Frandsen will present ExpreS²ion to investors and potential investors. Registration is possible via the [BioStock website](#).

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS²ion owns 34%. For additional information, please visit www.expres2ionbio.com.